Nuvectra Corp (NVTR) Expected to Post Quarterly Sales of $13.72 Million

Share on StockTwits

Equities analysts expect Nuvectra Corp (NASDAQ:NVTR) to report $13.72 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Nuvectra’s earnings. The lowest sales estimate is $13.30 million and the highest is $14.51 million. Nuvectra reported sales of $13.15 million during the same quarter last year, which would suggest a positive year over year growth rate of 4.3%. The company is expected to report its next earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Nuvectra will report full-year sales of $57.61 million for the current year, with estimates ranging from $57.00 million to $58.52 million. For the next fiscal year, analysts forecast that the business will report sales of $70.97 million, with estimates ranging from $68.26 million to $76.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Nuvectra.

Nuvectra (NASDAQ:NVTR) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.18). The company had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $12.76 million. Nuvectra had a negative return on equity of 62.18% and a negative net margin of 98.77%.

A number of analysts have recently weighed in on the stock. ValuEngine downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. JMP Securities reduced their target price on shares of Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, May 2nd. They noted that the move was a valuation call. Raymond James reduced their target price on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Finally, BidaskClub downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $20.40.

Shares of Nuvectra stock traded down $0.22 during trading hours on Friday, reaching $5.16. The company’s stock had a trading volume of 6,325 shares, compared to its average volume of 328,204. Nuvectra has a one year low of $5.18 and a one year high of $25.17. The company has a quick ratio of 6.07, a current ratio of 6.60 and a debt-to-equity ratio of 0.56. The company has a market cap of $93.81 million, a PE ratio of -1.62 and a beta of -0.19.

In other Nuvectra news, Director David D. Johnson bought 20,000 shares of Nuvectra stock in a transaction dated Monday, May 6th. The shares were purchased at an average cost of $6.12 per share, for a total transaction of $122,400.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 2.90% of the company’s stock.

A number of large investors have recently modified their holdings of NVTR. PNC Financial Services Group Inc. grew its stake in Nuvectra by 231.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,318 shares of the company’s stock worth $54,000 after acquiring an additional 2,318 shares in the last quarter. BNP Paribas Arbitrage SA bought a new position in Nuvectra in the 1st quarter worth about $40,000. Metropolitan Life Insurance Co. NY grew its stake in Nuvectra by 356.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,108 shares of the company’s stock worth $83,000 after acquiring an additional 3,989 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in Nuvectra in the 1st quarter worth about $64,000. Finally, JPMorgan Chase & Co. grew its stake in Nuvectra by 89.4% in the 1st quarter. JPMorgan Chase & Co. now owns 8,375 shares of the company’s stock worth $92,000 after acquiring an additional 3,954 shares in the last quarter. Institutional investors own 82.58% of the company’s stock.

About Nuvectra

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

See Also: What is the price-to-earnings growth (PEG) ratio?

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report